MENU
 

PRE TAX NTA |$3.53

Value as at close of business on 7 March 2025

Perfect economic conditions for healthcare to thrive

 

Wealthy individual investors are bullish on healthcare stocks, but professional investment managers are split on whether the local sharemarket alone has sufficient diversity for those seeking portfolio exposure to the sector.

A survey of 400 sophisticated and wholesale investors by Citi in February found 46 per cent believe healthcare is the sector of the economy that shows “most promise” in the year ahead. The research was limited to sole or joint financial decision-makers with more than $2.5 million in net assets or annual income exceeding $250,000.

Almost 40 per cent of respondents indicated they hold shares in the healthcare sector, although the top three sectors most heavily featured in wealthy portfolios were finance, industrials and telecommunications.

The findings reflect stronger expectations for the performance of healthcare stocks among wealthier investors than even technology stocks, the best-performing sector in 2020.

Peter Moussa, investment specialist at Citi Australia, says survey respondents are right to have high expectations for healthcare.

“The future looks bright for healthcare,” Moussa tells The Australian Financial Review. “Citi expects demand for healthcare products and services to remain elevated due to the pandemic.”

He suspects that many high-net-worth investors are attracted to the sector partly because of the valuations on offer – especially compared to the technology sector, where market capitalisations, in 2020 at least, were being compared to the late 1990s “dotcom boom” (which preceded a bust).

“Healthcare stocks are relatively cheap in what is a broadly expensive market,” Moussa says.

“Overall the healthcare sector has lower volatility because of more predictable revenue streams. This is particularly true of stocks that have strong balance sheets.”

The market analyst’s comments relate to healthcare exposures on the Australian sharemarket.

While the investors surveyed were not asked to differentiate their expectations between local and global markets, 52 per cent said they limited their share portfolios to Australian companies, while 44 per cent held both local and international shares.

 

CSL heavily tipped

Jun Bei Liu, portfolio manager at Tribeca Investment Partners, believes there is plenty of opportunity for healthcare sector bulls exclusively hunting on the Australian sharemarket.

“We have very innovative companies in the Australian healthcare sector,” Ms Liu says.

Naturally, she points first to CSL, Australia’s largest healthcare company and among the top three companies in general, with a market capitalisation of $131.6 billion as at June 1.

The biotech giant, known for being the world’s largest collector of human blood plasma, has seen its shares surge by 145 per cent over the past five years. Having presided over the remarkable growth, its chief executive, Paul Perreault, was named Financial Review Business Person of the Year in 2019.

More recently, its shares have “underperformed”, Liu says, having declined by about 3 per cent over the past six months. But it remains “very interesting” and “one of the country’s greatest businesses”, she adds.

Equity analysts at Macquarie have an “outperform” rating on CSL, projecting its shares will rise by 8 per cent over the next 12 months off the back of increased foot traffic at its US-based blood collection centres.

Morgan Stanley analysts Sean Laaman and Megan Kirby-Lewis, however, tip CSL as likely to have a “strong rebound” in the 2023 financial year but faces uncertainty until then.

 

Other contenders

Given its size and global brand recognition, CSL can dominate conversation of Australian healthcare, Liu concedes. After all, it accounts for about 6.5 per cent of the S&P/ASX 200 index – let alone the S&P/ASX 200 Health Care Index.

But she says there are many other Australian healthcare companies batting above their weight, including in international markets.

Medical imaging company Pro Medicus, for example, was until recently considered a “small cap”. However, it is growing by the day, Liu says, partly due to its success abroad.

“There is lots of momentum behind this business,” she says. “It has incredible technology,” she adds, and is inking deals with “premium hospitals” around the world.

 

People are generally more health conscious and there is a baby boom on the cards as well.

— Jun Bei Liu, Tribeca Investment Partners

 

In January Pro Medicus secured its largest-ever contract, locking in a seven-year deal with Salt Lake City-based US healthcare group Intermountain worth $40 million.

Similarly, Ramsay Health Care has made moves abroad, forking out $1.8 billion to acquire British competitor Spire Healthcare in May.

“To me, that is really exciting because the UK is a market where private health insurance penetration is very, very low,” Liu says. “Ramsay have a lot of property sitting on the balance sheet that they could unlock” to deploy to similar growth opportunities, she said.

The private hospital owner and operator, founded by late Rich Lister Paul Ramsay in 1964, also looks relatively “cheap”, Liu adds, trading about 20 per cent below its five-year peak of $79.75 in February 2020.

It also has a good outlook for earnings growth as it emerges from the pandemic. To that end, Ramsay is a company that “plays in the COVID-19 reopening theme”, Liu says.

With private medical facilities shut and elective procedures cancelled for much of the past year, it has been a “pandemic loser” and is poised for a comeback as normal conditions resume.

That is not to say that the healthcare sector’s pandemic winners, such as New Zealand-based and Australian-listed Fisher & Paykel, will necessarily become losers, however.

Having experienced relatively slow traction selling its products into hospital emergency rooms around the world in recent years, the surging demand for its respiratory devices during the pandemic bodes well.

“The pandemic has actually brought forward the decision to adopt their products,” Liu says.

 

Global spectrum

More broadly, the sector is well-positioned to benefit from cultural changes and trends accelerated by the pandemic. “People are generally more health conscious and there is a baby boom on the cards as well,” Liu says.

Citi’s Moussa agrees. “In the longer term, [healthcare] revenues are further supported from changes in demographics such as the ageing population.”

However, Arian Neiron, managing director of exchange traded fund manager VanEck in the Asia-Pacific, questions whether healthcare investors can truly get exposure to the reopening theme and other positive trends without going global.

“You would want access to a diversity of segment and global names across the entire healthcare spectrum including, but not limited to, pharmaceutical, biotech, hospital/nursing management and other medical specialties,” he says.

For that reason, VanEck has not considered an ETF that tracks the Australian healthcare index. “It is way too concentrated across names and sub-segments,” Neiron says. “CSL would be over 60 per cent and also there are only 13 constituents.”

 

This article was originally posted on The Australian Financial Review here.

Licensed by Copyright Agency. You must not copy this work without permission.

Recent Posts

Read the latest insights
A curated list of HM1 investor updates, portfolio news and other interesting articles.
Read More
Reporting Season Insights: HM1 Core Portfolio Holdings
We spoke to our dedicated fund managers for an update on some of our major portfolio holdings following reporting season.
The investing megatrends you can’t ignore (and some you should rethink)
James Marlay of Livewire sat down with Vihari Ross of Antipodes (HM1 Conference Fund Manager) and James Tsinidis of Munro Partners (HM1 Core Fund Manager) to discuss the biggest megatrends shaping the future.
2025: Where to Find Market Opportunities
There are opportunities abound for investors with an active management mindset in 2025. Get more insights from one of HM1's Core Fund managers, Magellan.
Significant increase in profit and increased fully franked dividend
We're pleased to declare an increased half-year fully franked dividend of 8.0 cents per share payable in April 2025.
 

Reporting Season Insights: HM1 Core Portfolio Holdings

We spoke to our dedicated fund managers for an update on some of our major portfolio holdings following reporting season.

Read More
March 10th, 2025
 

The investing megatrends you can’t ignore (and some you should rethink)

James Marlay of Livewire sat down with Vihari Ross of Antipodes (HM1 Conference Fund Manager) and James Tsinidis of Munro Partners (HM1 Core Fund Manager) to discuss the biggest megatrends shaping the future.

Read More
March 3rd, 2025
 

2025: Where to Find Market Opportunities

There are opportunities abound for investors with an active management mindset in 2025. Get more insights from one of HM1's Core Fund managers, Magellan.

Read More
February 25th, 2025
 

Significant increase in profit and increased fully franked dividend

We're pleased to declare an increased half-year fully franked dividend of 8.0 cents per share payable in April 2025.

Read More
February 20th, 2025
 

Magellan's Elisa Di Marco - 3 Trends That Will Define The Next Decade

Elisa Di Marco of Magellan (HM1 Core Fund Manager) joined Equity Mates to unpack 3 big megatrends shaping our world today (and how we can invest in them).

Read More
February 7th, 2025
 

Nine top stock picks to prepare your portfolio for 2025

Health care, ride-sharing, and the emerging world of YouTube entertainers are among the industries leading investors have picked for growth in 2025.

Read More
January 21st, 2025
 

Resources fundies reveal top picks ahead of ‘stellar’ 2025

Some of Australia’s biggest resources funds are gearing up for a bumper start to the new year.

Read More
January 6th, 2025
 

Qiao Ma: finding killer companies, surviving the GFC & why founders win

Qiao Ma, Portfolio Manager of the Munro Partners joins Owen Rask on The Australian Investors Podcast.

Read More
January 6th, 2025
 

10 top fund managers reveal their long-term stock picks

With valuations stretched and geopolitical tensions high, the new year offers plenty of potholes for investors. 

Read More
December 28th, 2024
 

Rikki Bannan – Don’t get caught up in momentum

Conference Fund Manager Rikki Bannan, Executive Director at IFM Investors, joins Equity Mates to discuss her standout 2023 stock pick, Telix, and explore what opportunities lie ahead.

Read More
December 19th, 2024
 

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
December 10th, 2024
 

Nick Griffin – The Nvidia story is not over

Nick Griffin, Founding Partner & Chief Investment Officer of Munro Partners joined the Equity Mates podcast in their Summer Series.

Read More
December 9th, 2024
 

HM1 CEO Succession

Hearts and Minds Investments Limited advises that Paul Rayson intends to retire from the position of Chief Executive Officer, effective 19 February 2025.

Read More
December 5th, 2024
 

How Trump will impact equity markets

The United States has spoken. President Trump has returned to the White House. But how can we cut through the noise to reveal the investment, economic and geopolitical ramifications?

Read More
November 26th, 2024
 

Trump unifies top investors in decade-long bullish outlook for US

Nick Moakes, CIO of the $72 billion Wellcome Trust, told the conference that too many investors were banking on a return to the ultra-low interest rates that prevailed over the past decade.

Read More
November 20th, 2024
 

These rock-star stock picks could get markets talking next year

Eleven rock stars of international and local funds management took to stage – each tasked with picking and pitching one company whose shares will take off over the next year.

Read More
November 18th, 2024
 

Is anyone brave or stupid enough to bet against America?

Stock pickers have been punished for betting against the US. The choice between consensus and contrarianism on American exceptionalism is now harder than ever.

Read More
November 17th, 2024
 

Sohn: NYSE-listed Estee Lauder’s Northcape Capital pick

Northcape Capital’s Fleur Wright this gives a rare opportunity to buy a high quality company at an attractive price.

Read More
November 15th, 2024
 

Sohn ASX stock pick: Ellerston Capital’s Chris Kourtis backs Perpetual

Chris Kourtis has put his biggest bet on embattled Perpetual – picking one of the most hated stocks on the ASX – that he believes will soon be the ‘cheapest listed asset manager of scale in the universe’.

Read More
November 15th, 2024
 

AI start-ups a threat to incumbent big companies

Paul Bassat predicts emerging artificial intelligence companies will disrupt sectors and overtake established incumbent companies just as rapidly as the seismic shifts that took place when the internet emerged in the mid-1990s.

Read More
November 15th, 2024
 

Howard Marks and Sohn’s big stars reveal seven rules for investing

Among the stock picks and stunts at the Sohh Hearts & Minds event, Howard Marks and Nick Moakes provided investors with long-term rules for playing markets.

Read More
November 15th, 2024
 

Sohn investors position for bullish but bumpy Trump ride

Australia and the rest of the world must adjust to a new Trump presidency that will deliver an expected bull market but also disruption, with the leader in waiting prepared to “create pain” to get his way.

Read More
November 15th, 2024
 

Sohn stock picker experts name best shares to invest in for year ahead

‍Don’t overlook down and out silver miners, legacy skincare brands ready for a revival and a big financial company suffering from a severe case of shareholder wealth destruction.

Read More
November 15th, 2024
 

Eleven stock tips from Sohn to get you through 2025

“There’s no finer place for the finance festival than in the festival city,” said Matthew Grounds. He, along with fellow Barrenjoey co-executive chairman Guy Fowler and investor Gary Weiss, is one of Sohn’s driving forces.

Read More
November 15th, 2024
 

Sohn Hearts & Minds Investments fund targets $1.5bn valuation

‍Hearts & Minds Investments chair Chris Cuffe is hoping for HM1 to grow to more than $1.5bn in the next five years.

Read More
November 14th, 2024
 

Galaxy Digital CEO Mike Novogratz believes bitcoin will hit $US100k

Bitcoin’s bounce to record highs in recent days is only the beginning of a fresh surge higher for cryptocurrency, says US billionaire Mike Novogratz.

Read More
November 9th, 2024
 

Why this New York hedge fund manager sees opportunity in European stocks

Influential New York-hedge fund manager Ricky Sandler will turn to Europe for his next stock pick.

Read More
November 6th, 2024
 

Antipodes’ Ross says short-term wealth hinges on US election

The portfolio manager says defensive stocks pose a bigger risk than the magnificent seven for investors that are overexposed to the American sharemarket.

Read More
November 5th, 2024
 

Concentration risk key for investors: Antipodes Partners’ Vihari Ross

The concentration risk in global stock indexes that has built up during the strong rise over the past year must now be a key consideration for global investors, according to Vihari Ross.

Read More
November 5th, 2024
 

The fundie betting big on China – with help from AI

Mr Mehta is sticking to his well-worn strategy: he’s hunting for companies across Asia that aren’t battling intense competition and have management teams focused on costs, cash generation and high payouts to shareholders.

Read More
November 5th, 2024